SNU-182Homo sapiens (Human)Cancer cell line

Also known as: NCI-SNU-182, SNU182

🤖 AI SummaryBased on 9 publications

Quick Overview

Human hepatocellular carcinoma cell line with TERT promoter mutations and HBV integration.

Detailed Summary

SNU-182 is a human hepatocellular carcinoma (HCC) cell line established from a primary tumor of a 24-year-old male patient. It exhibits high-frequency TERT promoter mutations, including C228T and C250T, which are associated with increased telomerase activity and cellular immortality. The cell line also shows HBV DNA integration, suggesting a role in hepatocarcinogenesis. SNU-182 is used in studies investigating the molecular mechanisms of HCC, including the impact of viral infections and genetic alterations on tumor progression. Research on SNU-182 has contributed to understanding the role of TERT mutations in cancer development and therapeutic targeting strategies.

Research Applications

Molecular mechanisms of hepatocellular carcinomaTERT promoter mutations in cancerHBV integration in hepatocarcinogenesisTherapeutic targeting of telomerase

Key Characteristics

High-frequency TERT promoter mutationsHBV DNA integrationCellular immortalityRelevance to hepatocarcinogenesis
Generated on 6/14/2025

Basic Information

Database IDCVCL_0090
SpeciesHomo sapiens (Human)
Tissue SourceLiver[UBERON:UBERON_0002107]

Donor Information

Age24
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseaseAdult hepatocellular carcinoma
LineageLiver
SubtypeHepatocellular Carcinoma
OncoTree CodeHCC

DepMap Information

Source TypeATCC
Source IDACH-000483_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Ser215Ile (c.644G>T)Heterozygous-from parent cell line SNU-398

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10,12
D13S317
11,14
D16S539
11,13
D18S51
16
D21S11
29,34.2
D3S1358
16,18
D5S818
11,12
D7S820
11
D8S1179
10
FGA
22,24
Penta D
9
Penta E
20
TH01
9
TPOX
8,11
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

A pharmacogenomic landscape in human liver cancers.";

Hui L.-J.

Cancer Cell 36:179-193.e11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Gastroenterology 157:760-776(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

Cevik D., Yildiz G., Ozturk M.

World J. Gastroenterol. 21:311-317(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

Nat. Commun. 4:2218.1-2218.7(2013).

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Xu J.-C.

Hepatology 58:706-717(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Biology of SNU cell lines.";

Ku J.-L., Park J.-G.

Cancer Res. Treat. 37:1-19(2005).

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

Won Y.-J., Kim S.-T., Park J.-G.

Int. J. Cancer 67:898-902(1996).

Characterization of cell lines established from human hepatocellular carcinoma.

Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.

Int. J. Cancer 62:276-282(1995).

Web Resources